Outcomes and Treatment Sequences of Therapies with BCL2-and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

被引：2

作者：

Kutsch, Nadine ^{[1
,2
,3
]}

Ligtvoet, Rudy ^{[1
,2
,3
]}

Robrecht, Sandra ^{[1
,2
,3
]}

Linde, Hartmut

Illmer, Thomas

Doerfel, Steffen ^{[4
]}

Lipke, Joerg

Aldaoud, Ali

Schlag, Rudolf

Dengler, Jolanta

Al-Sawaf, Othman ^{[1
,2
,3
]}

Langerbeins, Petra ^{[1
,2
,3
]}

Cramer, Paula ^{[1
,2
,3
]}

Eichhorst, Barbara F. ^{[5
]}

Hallek, Michael ^{[1
,2
]}

Fischer, Kirsten ^{[1
,2
,3
]}

Fink, Anna Maria ^{[1
,2
,3
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

[3] Univ Cologne, German CLL Study Grp, Cologne, Germany

[4] Ctr Oncol Dresden, Freiberg, Meissen, Germany

[5] Univ Cologne, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185741

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)
Goergen, Ellinor
von Tresckow, Julia
Giza, Adam
Robrecht, Sandra
Fink, Anna-Maria
Fischer, Kirsten
Al-Sawaf, Othman
Fuerstenau, Moritz
Simon, Florian
Kutsch, Nadine
Nieper, Pascal
Tausch, Eugen
Ritgen, Matthias
Boettcher, Sebastian
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Langerbeins, Petra
Eichhorst, Barbara
Hallek, Michael
Cramer, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S354 - S355
[42] Fludarabine versus fludarabine plus cyclophosphamide as first line therapy of advanced chronic lymphocytic leukemia (CLL):: First interim analysis of a phase III study (CLL4 protocol) of the German CLL study group (GCLLSG).
Schmitt, BF
Bergmann, M
Busch, R
Wendtner, CM
Pasold, R
Anders, O
Sezer, O
Hurtz, HJ
Söling, U
Steinbrecher, C
Emmerich, B
Hallek, M
BLOOD, 2001, 98 (11) : 633A - 633A
[43] Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG)
Kovacs, Gabor
Boettcher, Sebastian
Bahlo, Jasmin
Kluth, Sandra
Ritgen, Matthias
Fink, Anna Maria
Stodden, Irene
Cramer, Paula
von Tresckow, Julia
Maurer, Christian
Doehner, Hartmut
Stilgenbauer, Stephan
Kneba, Michael
Fischer, Kirsten
Hallek, Michael
Eichhorst, Barbara
BLOOD, 2014, 124 (21)
[44] Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)
Cramer, Paula
Isfort, Susanne
Bahlo, Jasmin
Stilgenbauer, Stephan
Doehner, Hartmut
Bergmann, Manuela
Stauch, Martina
Kneba, Michael
Lange, Elisabeth
Langerbeins, Petra
Pflug, Natali
Kovacs, Gabor
Goede, Valentin
Fink, Anna-Maria
Elter, Thomas
Fischer, Kirsten
Wendtner, Clemens-Martin
Hallek, Michael
Eichhorst, Barbara
HAEMATOLOGICA, 2015, 100 (11) : 1451 - 1459
[45] Mode of progression correlates with further clinical outcome of chronic lymphocytic leukemia (CLL). A meta-analysis by the German CLL study group
Al-Sawaf, O.
Robrecht, S.
Bahlo, J.
Fink, A. M.
von Tresckow, J.
Cramer, P.
Langerbeins, P.
Kutsch, N.
Wendtner, C. M.
Fischer, K.
Eichhorst, B.
Goede, V.
Hallek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 138 - 138
[46] Sequential treatment with bendamustine, followed by obinutuzumab (GA101) and venetoclax (ABT-199) in patients with chronic lymphocytic leukemia (CLL): results of the CLL2-BAG phase-II-trial of the German CLL study group (GCLLSG)
Cramer, Paula
von Tresckow, Julia
Bahlo, Jasmin
Robrecht, Sandra
Al-Sawaf, Othman
Langerbeins, Petra
Engelke, Anja
Fink, Anna-Maria
Fischer, Kirsten
Seiler, Till
von Weikersthal, Ludwig Fischer
Hebart, Holger
Kreuzer, Karl-Anton
Rittgen, Matthias
Kneba, Michael
Wendtner, Clemens
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2017, 58 : 149 - 150
[47] Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)
Fuerstenau, Moritz
Hopfinger, Georg
Robrecht, Sandra
Fink, Anna-Maria
Al-Sawaf, Othman
Langerbeins, Petra
Cramer, Paula
Von Tresckow, Julia
Maurer, Christian
Kutsch, Nadine
Hoechstetter, Manuela
Dreyling, Martin
Lange, Elisabeth
Kneba, Michael
Stilgenbauer, Stephan
Doehner, Hartmut
Hensel, Manfred
Kiehl, Michael G.
Jaeger, Ulrich
Wendtner, Clemens-Martin
Goede, Valentin
Fischer, Kirsten
Hallek, Michael
Eichhorst, Barbara
Theurich, Sebastian
BLOOD, 2018, 132
[48] Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines
Mikulska, Malgorzata
Oltolini, Chiara
Zappulo, Emanuela
Bartoletti, Michele
Frustaci, Anna Maria
Visentin, Andrea
Vitale, Candida
Mauro, Francesca R.
BLOOD REVIEWS, 2024, 65
[49] Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)
Kutsch, Nadine
Bottcher, Sebastian
Robrecht, Sandra
Bahlo, Jasmin
Maurer, Christian
Lange, Elisabeth
Koppler, Hubert
Kiehl, Michael G.
Sokler, Martin
Schlag, Rudolf
Vehling-Kaiser, Ursula
Kochling, Georg
Ploger, Christoph
Gregor, Michael
Plesner, Torben
Oschlies, Ilske
Herling, Marco
Fischer, Kirsten
Dohner, Hartmut
Kneba, Michael
Wendtner, Clemens-Martin
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Fink, Anna Maria
Hallek, Michael
Klapper, Wolfram
Eichhorst, Barbara F.
BLOOD, 2017, 130
[50] Patients with chronic lymphocytic leukemia (CLL) and an early relapse do not benefit from treatment with (R-)CHOP or other chemo(immuno)therapies that contain three or more cytotoxic agents and/or an anthracycline - a metaanalysis of the German CLL Study Group (GCLLSG)
Cramer, P.
Isfort, S.
Bahlo, J.
Busch, R.
Langerbeins, P.
Fischer, K.
Fink, A-M
Goede, V
Elter, T.
Bergmann, M.
Stauch, M.
Stilgenbauer, S.
Wendtner, C-M
Hallek, M.
Eichhorst, B.
ONKOLOGIE, 2012, 35 : 98 - 99

← 1 2 3 4 5 →